Teleflex earnings release, August 6, 2026
Teleflex Reports
Second
Quarter Finan cial Results and Full Year 2026 Outlook
Completes Sale of OEM Business and Will Deploy Net Proceeds to Reduce Debt and Repurchase Common Stock
Announces $250 Million Accelerated Share Repurchase Program, Repurchased $250 Million of Common Stock in the Second Quarter
Wayne, PA --
Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 30, 2026.
Second quarter 2026 continuing operations financial summary¹
• Revenue from continuing operations of $570.3 million, up 28.9% compared to the prior year period, and up 4.7% on a pro forma adjusted constant currency basis
1,2
• GAAP diluted EPS from continuing operations of $0.96, compared to $1.54 in the prior year period
• Adjusted diluted EPS from continuing operations of $1.76, compared to $1.73 in the prior year period
"We delivered a strong second quarter, led by excellent performance in our Vascular and Surgical businesses, while continuing to take decisive actions to strengthen the company for the future,” said Jason Weidman, Teleflex's President and Chief Executive Officer. “The completion of the OEM divestiture marks a pivotal step in our transformation, enabling greater focus on our core businesses, a stronger balance sheet, and increased financial flexibility to further reduce debt, return capital to shareholders, and invest in the opportunities that will drive long-term growth. We also made meaningful progress advancing our innovation pipeline, including important milestones for Freesolve and the Food and Drug Administration approval for EZPLAZ, reinforcing our commitment to bringing differentiated solutions to the market.”
Mr. Weidman continued, "Integration of the acquired Biotronik Vascular Intervention business is progressing, though taking longer than expected, and we updated our revenue outlook accordingly. Importantly, the delay is attributable to elongated integration timelines and not the underlying product portfolio, which remains competitively well positioned. We remain confident in the long-term strategic and financial prospects of this business as part of Teleflex, and have a number of mitigation actions underway to address the primary drivers of the delay. Our updated outlook also reflects the benefits of our disciplined capital allocation actions, including an increase to our adjusted EPS guidance."
Turning to his priorities as CEO, Weidman said: "I’m encouraged by the progress our team is making across the organization. Looking ahead, I am focused on completing a thorough assessment of the business and sharpening our strategic and operating plan to maximize shareholder value. My priorities are operational rigor, accelerating our innovation-driven¹ platforms, and disciplined capital deployment. We believe these efforts will position Teleflex to deliver a meaningfully stronger financial profile in 2027 and beyond."
2026 continuing operations guidance summary¹
• Reducing GAAP revenue growth guidance range to 13.40% to 14.40%
• Reducing GAAP EPS from continuing operations guidance range to $2.54 to $2.84
• Reducing pro forma adjusted constant currency revenue growth guidance range to 3.50% to 4.50%²
• Increasing Adjusted diluted EPS from continuing operations guidance range to $6.90 to $7.20
◦ Includes an assumption of approximately 19% adjusted operating margin for 2026 inclusive of transition services ("TS") associated with the close of the OEM Strategic Divestiture
◦ Reflects execution of capital allocation strategy including $250 million of share repurchase activity in the second quarter of 2026 and pay off of ~$700 million Term Loan A-2
◦ Excludes expected benefits from TS and manufacturing services ("MS") agreements that come into effect upon closing the Acute Care and Interventional Urology Strategic Divestiture
◦ Excludes the impact of the announced $250 million Accelerated Share Repurchase and other anticipated future repurchases under previously announced $1 billion share repurchase program primarily funded with proceeds from the Strategic Divestitures
◦ Adjusted diluted EPS from continuing operations excludes any impact of potential IEEPA tariff refunds
Financial statements
Income Statement
Forecasted 2026 Adjusted Diluted Earnings Per Share From Continuing Operations Reconciliation
| Low | High | |
|---|---|---|
| Forecasted GAAP diluted earnings per share from continuing operations | 2.54 | 2.84 |
| Restructuring and optimization items, net of tax | 0.98 | 0.98 |
| Acquisition, integration and divestiture related items, net of tax | 0.73 | 0.73 |
| Other items, net of tax | -0.42 | -0.42 |
| ERP implementation, net of tax | 0.31 | 0.31 |
| MDR, net of tax | 0.02 | 0.02 |
| Intangible amortization expense, net of tax | 2.74 | 2.74 |
| Forecasted adjusted diluted earnings per share from continuing operations, net of tax | 6.9 | 7.2 |
Income Statement
Three Months Ended — (Unaudited) (Dollars and shares in thousands, except per share)
| Three Months Ended – June 30, 2026 – (Dollars and shares in thousands, except per share) | Three Months Ended – June 29, 2025 – (Dollars and shares in thousands, except per share) | Six Months Ended – June 30, 2026 – (Dollars and shares in thousands, except per share) | Six Months Ended – June 29, 2025 – (Dollars and shares in thousands, except per share) | ||
|---|---|---|---|---|---|
| Net revenues | 570,332 | 442,525 | 1,118,594 | 856,783 | |
| Cost of goods sold | 238,625 | 176,695 | 479,461 | 335,522 | |
| Gross profit | 331,707 | 265,830 | 639,133 | 521,261 | |
| Selling, general and administrative expenses | 213,515 | 137,504 | 439,527 | 290,419 | |
| Research and development expenses | 45,122 | 26,488 | 89,508 | 51,783 | |
| Restructuring charges, separation costs and impairment charges | 246 | 10,700 | 17,091 | 12,122 | |
| Income from continuing operations before interest, taxes and loss on extinguishment of debt | 72,824 | 91,138 | 93,007 | 166,937 | |
| Interest expense | 27,953 | 21,703 | 53,671 | 40,240 | |
| Interest income | -1,416 | -1,229 | -3,124 | -2,717 | |
| Loss on extinguishment of debt | 1,150 | 1,150 | |||
| Income from continuing operations before taxes | 45,137 | 70,664 | 41,310 | 129,414 | |
| Taxes on income from continuing operations | 3,375 | 2,489 | 4,386 | 8,906 | |
| Income from continuing operations | 41,762 | 68,175 | 36,924 | 120,508 | |
| Operating income from discontinued operations | 60,254 | 64,577 | 57,611 | 114,637 | |
| Taxes on operating income from discontinued operations | 2,323 | 10,172 | 2,996 | 17,563 | |
| Income from discontinued operations | 57,931 | 54,405 | 54,615 | 97,074 | |
| Net income | 99,693 | 122,580 | 91,539 | 217,582 | |
| Basic: | Income from continuing operations | 0.96 | 1.54 | 0.84 | 2.68 |
| Basic: | Income from discontinued operations | 1.33 | 1.23 | 1.24 | 2.15 |
| Basic: | Net income | 2.29 | 2.77 | 2.08 | 4.83 |
| Diluted: | Income from continuing operations | 0.96 | 1.54 | 0.84 | 2.67 |
| Diluted: | Income from discontinued operations | 1.32 | 1.23 | 1.24 | 2.15 |
| Diluted: | Net income | 2.28 | 2.77 | 2.08 | 4.82 |
| Weighted average common shares outstanding | Basic | 43,562 | 44,269 | 43,908 | 45,017 |
| Weighted average common shares outstanding | Diluted | 43,660 | 44,332 | 44,014 | 45,120 |
Balance Sheet
June 30, 2026 — (Unaudited) (in thousands)
| June 30, 2026 | December 31, 2025 | ||
|---|---|---|---|
| Current assets | Cash and cash equivalents | 300,159 | 378,564 |
| Current assets | Accounts receivable, net | 364,609 | 345,583 |
| Current assets | Inventories | 351,912 | 404,395 |
| Current assets | Prepaid expenses and other current assets | 148,222 | 150,678 |
| Current assets | Prepaid taxes | 36,458 | 19,566 |
| Current assets | Current assets of discontinued operations | 674,516 | 639,552 |
| Current assets | Total current assets | 1,875,876 | 1,938,338 |
| Current assets | Property, plant and equipment, net | 475,637 | 498,281 |
| Current assets | Operating lease assets | 77,158 | 91,817 |
| Current assets | Goodwill | 2,292,435 | 2,305,050 |
| Current assets | Intangible assets, net | 1,448,669 | 1,524,150 |
| Current assets | Deferred tax assets | 12,642 | 12,593 |
| Current assets | Other assets | 120,310 | 112,984 |
| Current assets | Non-current assets of discontinued operations | 484,051 | 464,026 |
| Current assets | Total assets | 6,786,778 | 6,947,239 |
| Current liabilities | Current borrowings | 87,500 | 100,000 |
| Current liabilities | Accounts payable | 143,292 | 130,201 |
| Current liabilities | Accrued expenses | 134,170 | 117,350 |
| Current liabilities | Payroll and benefit-related liabilities | 110,214 | 124,769 |
| Current liabilities | Accrued interest | 3,558 | 5,404 |
| Current liabilities | Income taxes payable | 17,787 | 18,787 |
| Current liabilities | Other current liabilities | 88,364 | 137,195 |
| Current liabilities | Current liabilities of discontinued operations | 135,494 | 128,320 |
| Current liabilities | Total current liabilities | 720,379 | 762,026 |
| Current liabilities | Long-term borrowings | 2,720,509 | 2,541,449 |
| Current liabilities | Deferred tax liabilities | 146,141 | 183,749 |
| Current liabilities | Noncurrent liability for uncertain tax positions | 3,802 | 3,536 |
| Current liabilities | Noncurrent operating lease liabilities | 64,540 | 84,210 |
| Current liabilities | Other liabilities | 174,899 | 194,532 |
| Current liabilities | Non-current liabilities of discontinued operations | 51,974 | 52,969 |
| Current liabilities | Total liabilities | 3,882,244 | 3,822,471 |
| Commitments and contingencies | Total shareholders' equity | 2,904,534 | 3,124,768 |
| Commitments and contingencies | Total liabilities and shareholders' equity | 6,786,778 | 6,947,239 |
Cash Flow
Six Months Ended — (Unaudited) (in thousands)
| Six Months Ended – June 30, 2026 | Six Months Ended – June 29, 2025 | ||
|---|---|---|---|
| Cash flows from operating activities of continuing operations: | Net income | 91,539 | 217,582 |
| Adjustments to reconcile net income to net cash provided by operating activities: | (Income) loss from discontinued operations | -54,615 | -97,074 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Depreciation expense | 35,620 | 24,840 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Intangible asset amortization expense | 67,943 | 50,668 |
Full release
(1) Continuing operations excludes the Acute Care, Interventional Urology, and OEM businesses that were classified as discontinued operations during the fourth quarter of 2025 as a result of our entry into agreements to divest those businesses, which we refer to as the “Strategic Divestitures".
(2) Pro forma adjusted constant currency revenue growth includes revenue generated by the acquired Vascular Intervention business in the prior year period, and excludes (a) revenue generated by products previously included within continuing operations that were discontinued at the end of 2025 due to a strategic realignment, (b) the impact of the Italian payback measure, and (c) the impact of foreign exchange.
INNOVATION PIPELINE UPDATE
EZPLAZ BLA Approval
In late July, Teleflex received BLA approval from the U.S. Food and Drug Administration for EZPLAZ™ Freeze Dried Plasma, the first freeze-dried plasma licensed by the FDA. EZPLAZ expands the emergency medicine portfolio within the Company’s Vascular business and is approved for transfusion in adults with bleeding-related conditions requiring replacement of plasma coagulation factors, including uncontrolled bleeding (hemorrhage) when plasma is required and other plasma products are unavailable, including in combat and prehospital settings.
Freesolve Clinical Program Advances... (truncated) randomized controlled trial of Freesolve conducted outside the United States, positioning the Company for a data readout in late 2027; and initiated the U.S. BIOMAG-III pivotal trial, with first patient procedures completed in June at MedStar Washington Hospital Center.